Item 7.01 Regulation FD Disclosure.
On November 22, 2022, Marker Therapeutics, Inc. (the “Company”) issued a press
release (the “Press Release”) announcing that the U.S. Food and Drug
Administration had cleared the Company’s Investigational New Drug application
for MT-601 for the treatment of pancreatic cancer. A copy of this Press Release
is furnished herewith as Exhibit 99.1 to this Form 8-K and is incorporated
herein by reference.
The information contained in this Item 7.01 of the Form 8-K, including
Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), and is not incorporated by reference into any of the Company’s filings
under the Securities Act of 1933, as amended, or the Exchange Act, whether made
before or after the date hereof, except as shall be expressly set forth by
specific reference in any such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description
99.1 Press release, dated November 22, 2022
104 Inline XBRL for the cover page of this Current Report on Form 8-K
© Edgar Online, source Glimpses